摘要
目的 :观察对米托蒽醌聚乳酸毫微粒肝靶向制剂 (DHAQ PLA NP)的抗肝癌活性及毒理。方法 :采用常位移植鼠肝癌瘤株的小鼠肝癌模型 ,(DHAQ PLA NP)的抗肝癌活性进行了研究。结果 :显示DHAQ PLA NP对H2 2 实体型肝癌的抑瘤率高于DHAQ水针剂。用免疫组化 (HIC)SP法染色显示肿瘤增殖细胞 ,计算阳性百分率 ,DHAQ PLA NP组增殖细胞阳性率低于DHAQ水针剂组 ,说明靶向制剂具有良好的抗增殖细胞活性。测定靶向制剂的LD50 为 1 5 7mg·kg 1,与水针剂LD50 文献值 1 3 6mg·kg 1比较[1] ,表明靶向制剂毒性与水针剂接近。结论 :DHAQ PLA NP有良好的肝靶向性 。
The anti hepatocellular tumour activity of the liver targeted mitoxantrone polylactic acid extended release nanoparticles (DHAQ PLA NP) was tested by using orthtopic transplanting hepatocellular carcinoma model in mice. The rrate of tumour inhibition of DHAQ PLA NP is 12.8% higher than that of the DHAQ injection. The anti proliferating cell activity of DHAQ PLA NP was also higher than that of the DHAQ injection. The acute toxicity test showed the LD 50 of DHAQ PLA NP is 15.7mg·kg 1 . It is higher than the LD 50 (13.6mg·kg 1 ) of DHAQ injection. This result indicates the toxicity of DHAQ PLA NP is lower of not higher than that of DHAQ injection.
出处
《四川生理科学杂志》
2002年第1期30-32,共3页
Sichuan Journal of Physiological Sciences
关键词
米托蒽醌
聚乳酸毫微粒
肝靶向制剂
抗肝癌活性
Orthtopic transplanting
Hepatocellular carcinoma model
Polylactic acid extended release nanoparticles
Liver targeted preparations
